GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Valuation Rank

CSL (CSLLY) Valuation Rank


View and export this data going back to 2008. Start your Free Trial

What is CSL Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

CSL Valuation Rank Related Terms

Thank you for viewing the detailed overview of CSL's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Valuation Rank
Comparable Companies
ASX:TLX ASX:NEU ASX:MSB ASX:CU6 ASX:CUV ASX:IMU ASX:IMM ASX:OPT ASX:PYC ASX:BOT OCSE:NOVO B VRTX REGN MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX OCSE:GMAB
Traded in Other Exchanges
CMXHF:USA CSJ:Germany CSL:Australia
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
Website
https://www.csl.com
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.